



ASX Announcement

Appendix 3Y-Dr Bill Garner

11 March 2020 – The Board of Race Oncology Limited (ASX: RAC) authorised the sale of 4,000,000 fully paid ordinary shares by Dr Bill Garner on Friday 6 March 2020 at a price of \$0.30 per share. This sale will enable Merchant Opportunities Fund to become a significant holder in the Company while avoiding unnecessary dilution to shareholders.

The Board is fully committed to minimising shareholder dilution at all times and continues to strengthen the Company's shareholder base by attracting strategic, long term institutional investors, such as the Merchant Opportunities Fund.

The Appendix 3Y is attached.

- ENDS -

About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II cancer drug called Bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

Peter Molloy, Managing Director

plmolloy@raceoncology.com

Media contact:

Heidi Cuthbert

+61 411 272 366

heidi.cuthbert@multiplier.com.au

Released through: Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Race Oncology Limited
ABN	61 149 318 749

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	William James Garner
Date of last notice	26 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	2. Citicorp Nominees Pty Ltd – Beneficial Interest
Date of change	6 March 2020
No. of securities held prior to change	1. 17,705,078 Ordinary Shares 757,575 Options exercisable at \$0.099, expiring 31/08/2021 1,000,000 Options exercisable at \$0.25, expiring 25/11/2021 2. 225,000 Ordinary Shares
Class	Ordinary Shares
Number acquired	Nil
Number disposed	1. 4,000,000
Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$1,194,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	1. 13,705,078 Ordinary Shares 757,575 Options exercisable at \$0.099, expiring 31/08/2021 1,000,000 Options exercisable at \$0.25, expiring 25/11/2021 2. 225,000 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off-market transaction – sale to strategic investor.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.